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ymphadenectomy has long been part of the standard
reatment for breast cancer in patients with axillary node
nvolvement. Complete axillary lymphnodedissection (ALND)
rovides valuable information for staging as the number of
ositive nodes is an indicator of risk. Patients with nodal
nvolvement are at high risk of both locoregional recurrence
nd distant metastasis, and this risk increases with the num-
er of involved nodes. Despite the widely recognized value
f ALND in locoregional control and as a prognostic tool, the
isk of complications from surgery (lymphedema, seroma, and
nfection) is signiﬁcant. An alternative strategy is to perform
entinel lymph node dissection (SLND),1 which is also useful
or staging but with less morbidity.
In cases with 4 or more diseased nodes, axillary radiother-
py is clearly indicated. However, this indication is less certain
n cases with 1–3 positive nodes. The decision to irradiate,
nd the areas to be irradiated, has traditionally depended on
ther risk factors (tumor size, histological grade, nodal status,
ormone receptor status, Ki-67, and HER-2).2–6
However, with the recent publication of the two landmark
tudies mentioned above,7,8 it now appears that it is time to
ethink our view of what standard treatment for breast cancer
hould be. Giuliano et al.7 reported the ﬁndings of the Ameri-
an College of Surgeons Oncology Group (ACOSOG) Z0011 trial,
phase III randomized controlled trial (RCT) to evaluate the
ffect of axillary dissection on survival in women with inva-
ive breast cancer and sentinel node metastasis. The other
tudy, by Whelan et al.,8 presented ﬁndings from the MA.20
rial carried out by the National Cancer Institute of Canada
linical Trials Group (NCIC-CTG). The MA.20 study was a mul-
icentric RCT designed to evaluate the value of regional nodal
rradiation in early stage breast cancer.The ACOSOG Z0011 study included clinical stage T1–T2
nvasive breast cancer patients with no palpable adenopa-
hy and 1–2 sentinel nodes containing metastases. All
atients underwent lumpectomy and tangential-ﬁeldradiation therapy,9 and were randomized to undergo ALND
(10 or more nodes) or no further axillary treatment. Systemic
therapy was at the discretion of the treating physician. The
primary and secondary endpoints were overall survival (OS)
and disease-free survival (DFS). Findings showed no signiﬁ-
cant between-group differences in OS (91.8% with ALND vs.
92.5% with SLND alone) or DFS (82.2% vs. 83.9%). Given the
signiﬁcant morbidity of ALND, the clear implication of this
study is that ALND may be unnecessary in these patients with
these characteristics. For radiation oncologists, this change in
surgical approach has implications for treatment decisions as
we will no longer precisely know the extent of disease spread
to the axillary lymph nodes.
The NCIC-CTG MA.20 trial included 1832 women (916 in
each group), with a median follow-up of 62 months. The aim
was to evaluate the addition of regional nodal irradiation (RNI)
to WBI following BCS in women with high risk breast cancer,
regardless of sentinel node status. Patients were randomized
to WBI or WBI plus RNI to the internal mammary, supraclavic-
ular, and high axillary lymph nodes. Compared to WBI alone,
the combined therapy (WBI+RNI) showed an improvement
in isolated locoregional DFS, distant DFS, and OS. However,
the addition of RNI to WBI resulted in more toxicity (an
increase in grade 2 or greater pneumonitis and lymphedema).
The authors conclude that additional RNI reduces the risk
of locoregional and distant recurrence, improves DFS, and
shows a positive trend towards better OS. The results of the
MA.20 trial make it clear that adding RNI decreases recur-
rences in women with early-stage breast cancer. The ﬁndings
are important because they highlight the value of increasing
the radiation ﬁeld in patients with similar characteristics. Pre-
viously, the value of doing this was not clear.10,11
The results of these two studies are welcome news to
patients and physicians alike, because far fewer patients will
need to suffer from the morbidity (in particular, lymphedema)
associated with ALND from a procedure whose value is more
prognostic than curative. In fact, recently, the NCCN have
updated their guidelines (v1.2112) to bring recommendations
in line with the ACOSOG Z0011 ﬁndings. The NCCN now rec-
ommends that surgically operated (BCS) stage T1/T2 patients
d rad120 reports of practical oncology an
with only 1 or 2 positive sentinel nodes andnopreviousneoad-
juvant chemotherapy not receive ALND.
However, from the perspective of the radiation oncologist,
theﬁndings of these two important studiesmean thatwemust
now create new guidelines to incorporate the results into our
treatment decisions. Moreover, we need to decide what areas
of the body should be irradiated in these cases. Traditionally,
radiation oncologists have relied on ALND to provide data on
the exact number of diseased nodes. This information was
then used to select the appropriate radiotherapy approach:
when there is a clinically relevant risk, irradiation is performed
at the level of the supraclavicular chain and level III axillae.
Until these two studieswere published, irradiationwasper-
formed only in patients with either 4 or more positive nodal
biopsies or, in selected patients with 1–3 node-positive biop-
sies. However, with the publication of Z0011, it is not clear
– at least at present – as to which is the optimal radiation
ﬁeld to use in patients with positive sentinel nodes who have
not undergone lymphadenectomy. Haffty et al.12 believe we
should still consider total nodal irradiation in these patients.
As these authors point out, less than 1% of patients had
regional recurrence in Z0011, even though it was estimated
that more than 1 in 4 patients had additional positive nodes
(which were not dissected per the study protocol). In addition,
chemotherapy likely played an important role in destroy-
ing the nodal disease because systemic treatment has been
shown to achieve complete response in up to 25%of cases.13–15
Another possible reason for the low relapse rate may have
been the use of tangential ﬁelds through which axillary levels
I and II were probably irradiated, even if coincidentally. Haffty
and colleagues make an excellent point: we must consider
the radiation ﬁelds and patient positioning when deciding
whether to irradiate additional and larger areas. The Z0011
study does not tell us whether the lower axillae (levels I and
II) received a therapeutic dose, but this analysis is being per-
formed now.
Thus, in many ways, these ﬁndings actually create more
uncertainty for radiation oncologists. The indication for radio-
therapy is still unclear in patients with positive sentinel node
biopsy without ALDN.
2. Indication for irradiation in patients with
1–3 positive nodes
Prior to publication in 2005 of the Oxford meta-analysis,
which showed a survival beneﬁt of irradiating the supraclav-
icular area in all patients with involved lymph nodes, this
treatment was indicated only in patients with 4 or more
positive nodes as determined by ALND. Subsequently, sev-
eral studies have found a beneﬁt of adding adjuvant RT to
surgery and systemic treatment. Among these is the study
by Ragaz et al. for the British Columbia Cancer Agency
(BCCA).16 In that RCT, the investigators assessed the impact of
locoregional RT in premenopausal lymph node-positive breast
cancer patients. These authors found a clear beneﬁt of adju-
vant radiotherapy in reducing locoregional recurrences and
improved survival. Another similar RCT, carried out by Over-
gaard and colleagues,17 assessed the effect of irradiation on
survival after mastectomy. Once again, these authors foundiotherapy 1 7 ( 2 0 1 2 ) 119–121
a clear beneﬁt: locoregional recurrence alone or with distant
metastases was observed in only 9% of the RT group vs. 32% of
the chemotherapy group, DFS was better in the RT group (48%
vs. 34%), and 10 year OS was also superior (54% vs. 45%).
Of these 2 RCTs, only the one by the BCCA showed that
irradiation improved survival in all patients, regardless of
the number of positive nodes. For this reason, international
guidelines determined that there was insufﬁcient evidence to
support irradiating the nodal areas in patients with only 1–3
positive nodes. Until very recently, most consensus and clini-
cal practice guidelines recommended axillary irradiation only
in patients with 4+ positive nodes, but not in patients with
only 1–3 nodes. The reasoning behind this is that even though
radiation might reduce locoregional recurrence, it would be
unlikely to improve survival. Overgaard,18 in response to some
critical comments about the ﬁrst Danish studies, decided to
perform a retrospective analysis of the subgroup of node-
positive patients from the Danish Breast Cancer Cooperative
Group 82 (DBCG 82b and 82c). In that retrospective analy-
sis, the authors only included patients who had had 8 or
more nodes removed (a total of 1152 patients). The aim was
to evaluate the loco-regional recurrence rate and survival as
a function of the number of positive nodes. The authors found
that postmastectomy RT yielded an important survival bene-
ﬁt (15 year OS rate of 39% in patients with RT vs. 29% in those
without) and this advantage was maintained in patients with
1–3 and 4+ positive lymph nodes. The authors concluded that
the indication for RT seems to be at least equally beneﬁcial
in patients with 1–3 positive nodes, and they recommended
updating guidelines accordingly.
Based on these results, we considered the possibility of
performing RT to the supraclavicular chain in patients with
1–3 affected nodes when some other risk factor was present.
Currently, there are two randomized trials underway, the
SUPREMO (Selective Use of Postoperative Radiotherapy after
Mastectomy) and the aforementioned MA.20 (National Can-
cer Institute of Canada Clinical Trials), both of which aim to
clarify the role of RT in patients with intermediate risk who
have undergone a radical mastectomy (pT2 N0, grade 3 and/or
lymphovascular space invasion and 1–3 positive nodes).
3. Policy for lymph node irradiation at the
Catalan Institute of Oncology (Barcelona, Spain)
At our institute we use the following criteria to rule out ALND
when the sentinel node biopsy is positive: stage pT1 or pT2
with 1 or 2 positive sentinel nodes; no microscopic involve-
ment of the perinodal fat; BCS; adjuvant conventional breast
RT and adjuvant chemotherapy. Within this group of patients,
we have deﬁned a series of prognostic factors that determine
the type of radiotherapy to be performed: patients >50 years
with positive hormonal receptors and histological grade 1 or 2
tumors will undergo radiotherapy with high tangential ﬁelds;
patients <age 50 or with RH-negative or histological grade III
tumors are considered high risk and all nodal chains (levels
I, II, III and the ipsilateral supraclavicular area) will be irradi-
ated. Finally, patients with microscopic disease in the sentinel
node (pN1mic) do not undergo ALND, nor irradiation of levels I
and II.
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. Conclusion
ocoregional treatment of breast cancer is currently undergo-
ng important changes. With the recent publication of MA.20
nd the ACOSOG Z0011 studies, we now have two separate
CTs with similar inclusion criteria. Data on the RT ﬁelds
sed in these studies are not yet available and so we must
wait more data to ultimately decide if all N1 patients should
ndergo irradiation of the supraclavicular chain and level III.
owever, the data published to date is surely sufﬁcient to
rompt us to seriously consider increasing the volumes to
e irradiated in early stage breast cancer. By doing so, we are
ikely to improve both local control and survival.
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